{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:09:05Z","timestamp":1793311745351,"version":"4.5.0"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK R&D"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Pazopanib is an anti-angiogenic small molecule tyrosine kinase inhibitor approved for use in the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. This review provides an overview of pazopanib pharmacokinetics and therapeutic drug monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Pazopanib exhibits a multifaceted pharmacokinetic profile characterized by low and pH-dependent solubility, non-linear absorption, and time-dependent decreases in systemic exposure. Research to date has revealed numerous intrinsic and extrinsic factors significantly influencing pazopanib pharmacokinetics, including food interactions, use of gastric acid suppressants, drug\u2013drug interactions with concomitant medications and genetic polymorphisms. Pazopanib plasma trough concentrations &amp;gt; 20.5 and\u2009\u2265\u200927\u00a0\u03bcg\/ml are associated with improved efficacy in patients with renal cell carcinoma and soft tissue sarcoma, respectively, and increased pazopanib systemic exposure is associated with increased incidence of drug-related adverse events (e.g. hypertension).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pazopanib exhibits large variability in systemic exposure and consequently, achieving systemic exposures within a therapeutic range for optimal efficacy while minimizing toxicity, can be challenging when a fixed dose is used. Therefore, therapeutic drug monitoring may be a promising tool to optimize the efficacy of pazopanib while limiting drug-related toxicities, through personalized dose adjustments guided by monitoring plasma pazopanib concentrations. Further exploration into the influence of additional factors on pazopanib pharmacokinetics is essential for advancing pharmacokinetic-guided dosing strategies and improve treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgaf095","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:53:07Z","timestamp":1766494387000},"source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics of pazopanib: a review of the determinants, influencing factors and the clinical importance of therapeutic drug monitoring"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3887-9120","authenticated-orcid":false,"given":"Nicki M","family":"Kyriacou","sequence":"first","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney , Sydney, New South Wales 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-0127","authenticated-orcid":false,"given":"Annette S","family":"Gross","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney , Sydney, New South Wales 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4674-0242","authenticated-orcid":false,"given":"Andrew J","family":"McLachlan","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney , Sydney, New South Wales 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"2026021208122171700_ref1","doi-asserted-by":"publisher","volume-title":"Prescribing Information: Pazopanib","author":"United States Food and Drug Administration","DOI":"10.1186\/s40780-025-00477-8"},{"key":"2026021208122171700_ref2","volume-title":"PDQ Renal Cell Cancer Treatment","author":"National Cancer Institute: PDQ\u00ae Adult Treatment Editorial Board"},{"key":"2026021208122171700_ref3","volume-title":"PDQ Soft Tissue Sarcoma Treatment","author":"National Cancer Institute: PDQ\u00ae Adult Treatment Editorial Board"},{"key":"2026021208122171700_ref4","doi-asserted-by":"crossref","first-page":"e70224","DOI":"10.1111\/cts.70224","article-title":"Inter-ethnic differences in the efficacy and safety of tyrosine kinase inhibitors used in oncology: insights from phase 3 clinical trials","volume":"18","author":"Kyriacou","year":"2025","journal-title":"Clin Transl Sci"},{"key":"2026021208122171700_ref5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1089\/thy.2019.0269","article-title":"An international phase 2 study of pazopanib in progressive and metastatic thyroglobulin antibody negative radioactive iodine refractory differentiated thyroid cancer","volume":"30","author":"Bible","year":"2020","journal-title":"Thyroid"},{"key":"2026021208122171700_ref6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/ijgc-2023-004781","article-title":"PAZEC: a Dutch gynaecological oncology group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer","volume":"34","author":"Westermann","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"2026021208122171700_ref7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/FTD.0000000000000141","article-title":"Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study","volume":"37","author":"Wit","year":"2015","journal-title":"Ther Drug Monit"},{"key":"2026021208122171700_ref8","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1158\/1078-0432.CCR-16-1255","article-title":"Individualized pazopanib dosing: a prospective feasibility study in cancer patients","volume":"22","author":"Verheijen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026021208122171700_ref9","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/bcp.13327","article-title":"Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib","volume":"83","author":"Lankheet","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2026021208122171700_ref10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00280-017-3463-x","article-title":"Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization","volume":"80","author":"Verheijen","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021208122171700_ref11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40262-016-0443-y","article-title":"Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients","volume":"56","author":"Yu","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2026021208122171700_ref12","volume-title":"Australian Public Assessment Report for Pazopanib Hydrochloride (Renal Cell Carcinoma)","author":"Therapeutic Goods Administration"},{"key":"2026021208122171700_ref13","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"2026021208122171700_ref14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/FTD.0000000000001206","article-title":"Therapeutic drug monitoring of pazopanib in renal cell carcinoma and soft tissue sarcoma: a systematic review","volume":"46","author":"Turjap","year":"2024","journal-title":"Ther Drug Monit"},{"key":"2026021208122171700_ref15","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/bcp.14580","article-title":"Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib","volume":"87","author":"Fukudo","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026021208122171700_ref16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/bcp.14185","article-title":"Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose","volume":"86","author":"Westerdijk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026021208122171700_ref17","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00280-013-2164-3","article-title":"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors","volume":"71","author":"Tan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021208122171700_ref18","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1021\/acs.molpharmaceut.8b00081","article-title":"Evaluation of pazopanib phase behavior following pH-induced supersaturation","volume":"15","author":"Sugihara","year":"2018","journal-title":"Mol Pharm"},{"key":"2026021208122171700_ref19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/00498254.2012.734642","article-title":"Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer","volume":"43","author":"Deng","year":"2013","journal-title":"Xenobiotica"},{"key":"2026021208122171700_ref20","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026021208122171700_ref21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10637-015-0304-9","article-title":"Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site","volume":"34","author":"Imbs","year":"2016","journal-title":"Investig New Drugs"},{"key":"2026021208122171700_ref22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2026021208122171700_ref23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijpharm.2012.05.038","article-title":"Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib","volume":"436","author":"Minocha","year":"2012","journal-title":"Int J Pharm"},{"key":"2026021208122171700_ref24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1124\/dmd.117.076554","article-title":"Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib","volume":"46","author":"Ellawatty","year":"2018","journal-title":"Drug Metab Disposition"},{"key":"2026021208122171700_ref25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1515\/dmdi-2013-0062","article-title":"Role of OATP-1B1 and\/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors","volume":"29","author":"Khurana","year":"2014","journal-title":"Drug Metabol Drug Interact"},{"key":"2026021208122171700_ref26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026021208122171700_ref27","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","article-title":"Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma","volume":"24","author":"Sternberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026021208122171700_ref28","article-title":"Abstract 7105: population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma, presented at PAGE (Population Approach Group in Europe)","author":"Baneyx","year":"2017"},{"key":"2026021208122171700_ref29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40262-020-00863-5","article-title":"Cost-neutral optimization of pazopanib exposure by splitting intake moments: a prospective pharmacokinetic study in cancer patients","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026021208122171700_ref30","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s10637-011-9725-2","article-title":"A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors","volume":"30","author":"Heath","year":"2012","journal-title":"Investig New Drugs"},{"key":"2026021208122171700_ref31","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/clpt.2010.199","article-title":"A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors","volume":"88","author":"Heath","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2026021208122171700_ref32","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/cpt.1515","article-title":"The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET study)","volume":"106","author":"Lubberman","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026021208122171700_ref33","volume-title":"Australian Product Information\u2014Votrient\u00ae (Pazopanib) Tablets","author":"Therapeutic Goods Administration"},{"key":"2026021208122171700_ref34","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1002\/ijc.33469","article-title":"The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure","volume":"148","author":"Krens","year":"2021","journal-title":"Int J Cancer"},{"key":"2026021208122171700_ref35","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10","author":"Smelick","year":"2013","journal-title":"Mol Pharm"},{"key":"2026021208122171700_ref36","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2026021208122171700_ref37","author":"GlaxoSmithKline","year":"2008"},{"key":"2026021208122171700_ref38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40262-018-0719-5","article-title":"Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients","volume":"58","author":"Bins","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026021208122171700_ref39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2131\/jts.38.349","article-title":"The CYP3A4 intron 6 C&gt;T polymorphism ( CYP3A4*22 ) is associated with reduced CYP3A4 protein level and function in human liver microsomes","volume":"38","author":"Okubo","year":"2013","journal-title":"J Toxicol Sci"},{"key":"2026021208122171700_ref40","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40262-023-01260-4","article-title":"CYP3A4*22 genotype-guided dosing of kinase inhibitors in cancer patients","volume":"62","author":"Van Eerden","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026021208122171700_ref41","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026021208122171700_ref42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mayocp.2012.10.020","article-title":"Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents","volume":"88","author":"Bowlin","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"2026021208122171700_ref43","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10637-012-9885-8","article-title":"Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors","volume":"31","author":"De Jonge","year":"2013","journal-title":"Investig New Drugs"},{"key":"2026021208122171700_ref44","doi-asserted-by":"publisher","volume-title":"Prescribing Information: Lapatinib","author":"United States Food and Drug Administration","DOI":"10.1002\/cncr.31382"},{"key":"2026021208122171700_ref45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00247","article-title":"Phase I trial of dabrafenib and pazopanib in BRAF mutated advanced malignancies","volume":"2","author":"Haraldsdottir","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026021208122171700_ref46","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/bjc.2013.798","article-title":"Pazopanib exposure decreases as a result of an ifosfamide-dependent drug\u2013drug interaction: results of a phase I study","volume":"110","author":"Hamberg","year":"2014","journal-title":"Br J Cancer"},{"key":"2026021208122171700_ref47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00685732","article-title":"The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion","volume":"36","author":"Boddy","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021208122171700_ref48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00280-015-2953-y","article-title":"Pharmacokinetic interaction between pazopanib and cisplatin regimen","volume":"77","author":"Imbs","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021208122171700_ref49","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1248\/bpb.b19-00560","article-title":"Possibility for dose optimization of pazopanib from its plasma concentration in Japanese patients with cancer","volume":"43","author":"Tanaka","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"2026021208122171700_ref50","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-12-3214","article-title":"Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute organ dysfunction working group study","volume":"19","author":"Shibata","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026021208122171700_ref51","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/07853890.2019.1693056","article-title":"Impaired albumin function: a novel potential indicator for liver function damage?","volume":"51","author":"Sun","year":"2019","journal-title":"Ann Med"},{"key":"2026021208122171700_ref52","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00280-014-2455-3","article-title":"Pharmacokinetics of pazopanib administered in combination with bevacizumab","volume":"73","author":"Imbs","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021208122171700_ref53","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1111\/bcp.13725","article-title":"Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?","volume":"84","author":"Crombag","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2026021208122171700_ref54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"2026021208122171700_ref55","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"Oncologist"},{"key":"2026021208122171700_ref56","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2026021208122171700_ref57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/ph14090927","article-title":"Population pharmacokinetic analysis of pazopanib in patients and determination of target AUC","volume":"14","author":"Ozbey","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2026021208122171700_ref58","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/j.clgc.2018.12.001","article-title":"Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma","volume":"17","author":"Noda","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"2026021208122171700_ref59","author":"GlaxoSmithKline","year":"2011"},{"key":"2026021208122171700_ref60","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40262-024-01399-8","article-title":"Evaluating the clinical impact and feasibility of therapeutic drug monitoring of pazopanib in a real-world soft-tissue sarcoma cohort","volume":"63","author":"Meertens","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2026021208122171700_ref61","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1158\/1078-0432.CCR-17-1873","article-title":"Individualized pazopanib dosing\u2014letter","volume":"23","author":"Bellesoeur","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026021208122171700_ref62","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061224","article-title":"Relation between plasma trough concentration of pazopanib and progression-free survival in metastatic soft tissue sarcoma patients","volume":"14","author":"Minot-This","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026021208122171700_ref63","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","article-title":"Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report","volume":"31","author":"Glade Bender","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026021208122171700_ref64","volume-title":"Pazopanib","author":"Australian Medicines Handbook (online)"},{"key":"2026021208122171700_ref65","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/1078-0432.CCR-15-2044","article-title":"HLA-B*57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer","volume":"22","author":"Xu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026021208122171700_ref66","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-025-01504-5","article-title":"Model-informed dose optimization of pazopanib in real-world patients with cancer","author":"Tan","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026021208122171700_ref67","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study","volume":"33","author":"Groenland","year":"2022","journal-title":"Ann Oncol"},{"key":"2026021208122171700_ref68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.3547","article-title":"Green tea catechins as perpetrators of drug pharmacokinetic interactions","volume":"118","author":"Kyriacou","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"2026021208122171700_ref69","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/2\/rgaf095\/66130868\/rgaf095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/2\/rgaf095\/66130868\/rgaf095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:12:30Z","timestamp":1770901950000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgaf095\/8405161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgaf095","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,26]]},"article-number":"rgaf095"}}